Clinical trial

Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients

NCT07709585

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-07-05

PhasePHASE2

Study timeline

Study start (estimated)2026-07-05Date precision: day

Registry last updated2026-07-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Non-small Cell Lung Cancer (NSCLC)unresolved

EGFR Exon 19 Deletion Mutationunresolved

EGFR Exon 21 Mutationunresolved

EGFR Exon 21 L858R Mutationunresolved

Interventions

Pemetrexed + Cisplatin /CarboplatinDRUG

Sponsors & collaborators

Guangzhou University of Traditional Chinese Medicinelead sponsor

Guangdong Provincial Hospital of Traditional Chinese Medicinecollaborator

Beijing Chest Hospitalcollaborator

Guang'anmen Hospital of China Academy of Chinese Medical Sciencescollaborator

Sichuan Cancer Hospital and Research Institutecollaborator

Yueyang Hospital of Integrated Traditional Chinese and Western Medicinecollaborator

First Affiliated Hospital of Xinjiang Medical Universitycollaborator

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07709585 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.